Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis.

[1]  F. Guisier,et al.  Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study. , 2024, Journal of Clinical Oncology.

[2]  J. Chaft,et al.  Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN. , 2024, Journal of Clinical Oncology.

[3]  Jifeng Sun,et al.  Chemoradiotherapy versus surgery after neoadjuvant chemoimmunotherapy in patients with stage III NSCLC: a real-world multicenter retrospective study , 2024, Cancer immunology, immunotherapy : CII.

[4]  Jingjing Kang,et al.  Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study , 2024, MedComm.

[5]  F. Dai,et al.  Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective , 2024, Thoracic cancer.

[6]  J. Rei,et al.  Outcomes Of Surgically Treated N2-Positive Non-Small Cell Lung Cancer. , 2024, Portuguese journal of cardiac thoracic and vascular surgery.

[7]  S. Jolly,et al.  Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT) , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Dingemans,et al.  P1.28-08 Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group , 2023, Journal of Thoracic Oncology.

[9]  A. Dingemans,et al.  OA06.05 Consensual Definition of Stage III NSCLC Resectability: EORTC-Lung Cancer Group Initiative with Other Scientific Societies , 2023, Journal of Thoracic Oncology.

[10]  L. Antonuzzo,et al.  Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. , 2023, The New England journal of medicine.

[11]  M. Satouchi,et al.  Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. , 2023, JAMA oncology.

[12]  M. Lanuti,et al.  Induction Chemoimmunotherapy with Surgery versus Concurrent Chemoradiation followed by Immunotherapy for Stage III-N2 Non-small Cell Lung Cancer. , 2023, Journal of Thoracic and Cardiovascular Surgery.

[13]  C. Dooms,et al.  Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. , 2023, The New England journal of medicine.

[14]  N. Yang,et al.  Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III Neotorch study. , 2023, Journal of Clinical Oncology.

[15]  Stanley J Tamaki,et al.  Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes , 2023, Cell.

[16]  Q. Xue,et al.  Induction Immune Checkpoint Inhibitors and Chemotherapy before Definitive Chemoradiation Therapy for Patients with Bulky Unresectable Stage III Non-small-cell Lung Cancer. , 2023, International journal of radiation oncology, biology, physics.

[17]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[18]  Desong Yang,et al.  A real‐world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non‐small cell lung cancer , 2022, Cancer medicine.

[19]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[20]  M. Nagasaka,et al.  Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations. , 2022, Clinical lung cancer.

[21]  T. Illidge,et al.  Immunomodulation by radiotherapy in tumour control and normal tissue toxicity , 2021, Nature Reviews Immunology.

[22]  Keunchil Park,et al.  Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer , 2021, JAMA oncology.

[23]  U. Dafni,et al.  Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14). , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  N. Hanna,et al.  A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179 , 2020, Cancer.

[25]  A. Melcher,et al.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy , 2020, Nature Reviews Cancer.

[26]  C. Simone,et al.  Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. , 2020, JAMA oncology.

[27]  Joe Y. Chang,et al.  Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  N. Hanania,et al.  Radiation-Induced Lung Injury: Assessment and Management. , 2019, Chest.

[29]  Li Zhang,et al.  Establishment of a prospective multicenter cohort for advanced non‐small cell lung cancer in China (CAPTRA‐Lung study) , 2018, Thoracic cancer.

[30]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[31]  Roy S. Herbst,et al.  The biology and management of non-small cell lung cancer , 2018, Nature.

[32]  A. Dicker,et al.  Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer , 2018, Clinical Cancer Research.

[33]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[34]  M. Stuschke,et al.  Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence , 2017, Oncotarget.

[35]  A. Giobbie-Hurder,et al.  Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.

[36]  A. Warth,et al.  The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institution. , 2015, Lung cancer.

[37]  Zhidong Liu,et al.  Randomized controlled trials of induction treatment and surgery versus combined chemotherapy and radiotherapy in stages IIIA-N2 NSCLC: a systematic review and meta-analysis. , 2015, Journal of thoracic disease.

[38]  Lan-Jun Zhang,et al.  Time-Varying Pattern of Postoperative Recurrence Risk of Early-Stage (T1a-T2bN0M0) Non-Small Cell Lung Cancer (NSCLC): Results of a Single-Center Study of 994 Chinese Patients , 2014, PloS one.

[39]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[40]  V. Mehta.  Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. , 2005, International journal of radiation oncology, biology, physics.